Patterns of Antibody Response in Humans to the Anthrax Vaccine Adsorbed (AVA) Primary (six-dose) Series
Abstract
The antibody profile during and after the six-dose primary vaccination series with anthrax vaccine adsorbed (AVA, BiothraxTM)was characterized in 86 human volunteers. Ninety-three percent of recipients developed IgG antibodies to Bacillus anthracis protective antigen (PA) after two doses, and 100% were seropositive after dose #3. Geometric mean concentrations (GMC) of IgG to PA measured before and after each dose were significantly lower after injection #3 (peak GMC = 146.65 micrograms /mL, trough GMC = 15.16 micrograms/mL) than after injections #4 (peak GMC = 430.46micrograms/mL, trough GMC 96.19 micrograms/mL) (p < 0.0001 for each); but not between injections #4, #5 and #6, or #4 and #6 (p <0.7923 for each). Decay rates for IgG to PA were significantly faster after infection #3 (half life [T1/2] 39.21 days) than after injections #4 (T1/2 = 70.14 days (p <0.0282 for each). Toxin neutralizing assay (TNA) antibody patterns generally paralled those for IgG to PA. The 6-month dose in the AVA primary series appears to be critical in sustaining IgG to PA concentrations in a substantial proportion of recipients.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 24, 2006
- Accession Number
- ADA449401
Entities
People
- David Bedwell
- Julio G. Oro
- Kelly T. Mckee
- Phillip R. Pittman
- Sarah L. Norris
- Timothy L. Cannon
Organizations
- United States Army Medical Research Institute of Infectious Diseases